Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Empagliflozin and Metformin Coadministration
NCT02172248Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2009
- Primary completion
- Mar 2009
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of empagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve at steady state up to 7 days and Maximum measured concentration at steady state up to 7 days. Started Jan 2009; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02172248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02172248.